Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Drosophila cryptochrome (dCry) is a flavin-containing photoreceptor. The release of C-terminal tail (CTT) upon illumination is a crucial step for the light sensing of dCry. Here, we demonstrated that both anionic semiquinone (asq) and anionic hydroquinone (hq) triggered CTT release, while neutral semiquinone (nsq) formation suppressed it. However, during photoreduction, a fraction of nsq was formed in dCry under neutral conditions, and the fraction of which increased when the pH decreased. The proton required for nsq formation might be transferred to flavin through a side tunnel. The nsq formation was minimized in dCry under basic conditions, or in the mutants in CTT, which resulted in enhanced CTT release but slower oxidation (i.e. recovery) after photoreduction. Therefore, forming a proper fraction of nsq is important for fast recovery of dCry after light sensing. Nevertheless, a key residue at the side tunnel, His378, is a proton interceptor that adjusts the nsq formation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335480 | PMC |
| http://dx.doi.org/10.1038/s42004-025-01647-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The ionic and protonation states of flavin control the activation and recovery of Drosophila cryptochrome.
Commun Chem
August 2025
Department of Biochemistry and Molecular Biology, School of Basic Medicine, Wannan Medical College, Wuhu, Anhui, China.
Drosophila cryptochrome (dCry) is a flavin-containing photoreceptor. The release of C-terminal tail (CTT) upon illumination is a crucial step for the light sensing of dCry. Here, we demonstrated that both anionic semiquinone (asq) and anionic hydroquinone (hq) triggered CTT release, while neutral semiquinone (nsq) formation suppressed it.
View Article and Find Full Text PDFMolecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
Lung Cancer
October 2024
Georgetown University, 3800 Reservoir Rd NW, Washington, D.C 20007, USA. Electronic address:
Objectives: MET exon 14 skipping alterations (METex14+) represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) with distinct biological and genomic features. We characterized this heterogeneity in a large cohort, integrating genomic and transcriptomic profiling with clinical outcomes, to elucidate the histologic and molecular traits and survival patterns of METex14+ NSCLC.
Materials And Methods: NSCLC tissue samples (n = 28,739) underwent DNA-based next-generation sequencing (592 genes, NextSeq) or whole-exome sequencing (NovaSeq), RNA-sequencing including whole transcriptome sequencing (WTS, NovaSeq), and PD-L1 IHC (Dako 22C3) at Caris Life Sciences.
First-line Treatment Patterns and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy.
Acta Oncol
April 2024
Department of Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Department of Genetics, Pathology, and Molecular Diagnostics, Skåne University Hospital, Lund, Sweden.
Background And Purpose: The treatment landscape for patients with advanced non-small cell lung cancer (NSCLC) has evolved significantly since the introduction of immunotherapies. We here describe PD-L1 testing rates, treatment patterns, and real-world outcomes for PD-(L)1 inhibitors in Sweden.
Materials And Methods: Data were obtained from the Swedish National Lung Cancer Registry for patients with advanced NSCLC and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 who initiated first-line -systemic treatment from 01 April 2017 to 30 June 2020.
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Front Immunol
November 2022
Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Introduction: Clinical evidence suggests that first-line immune checkpoint inhibitor (ICI) combination therapies can improve survival in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC). However, the optimal strategy remains unknown without a systematic comparison of their long-term effects.
Methods: We performed a systematic review and network meta-analysis by retrieving up-to-date literature from PubMed (National Library of Medicine, Bethesda, MD, USA), Embase (Elsevier, Amsterdam, Netherlands), MEDLINE (National Library of Medicine), ClinicalTrials.
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Ann Oncol
May 2022
Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
Background: Anti-programmed cell death protein (death-ligand) 1 [PD-(L)1] therapy alone [cancer immunotherapy (CIT)-mono] or combined with platinum-based chemotherapy (CIT-chemo) is used as the first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC). Our study compared clinical outcomes with CIT-mono versus CIT-chemo in the specific clinical scenario of non-squamous (Nsq)-NSCLC with a high PD-L1 expression of ≥50% [tumor proportion score (TPS) or tumor cells (TC)].
Methods: This was a retrospective cohort study using a real-world de-identified database.